http://Opengenome.net/index.php?action=history&feed=atom&title=%EB%89%B4%EC%A0%A0%EB%B9%84%EC%95%84%EC%9D%B4%ED%8B%B0_%EC%9E%90%ED%9A%8C%EC%82%AC_%EC%95%94%EC%B9%98%EB%A3%8C%EC%A0%9C_FDA_%EC%9E%84%EC%83%811%EC%83%81_%EC%8B%9C%ED%97%98_%EC%8A%B9%EC%9D%B8
뉴젠비아이티 자회사 암치료제 FDA 임상1상 시험 승인 - Revision history
2026-07-28T17:52:57Z
Revision history for this page on the wiki
MediaWiki 1.31.3
http://Opengenome.net/index.php?title=%EB%89%B4%EC%A0%A0%EB%B9%84%EC%95%84%EC%9D%B4%ED%8B%B0_%EC%9E%90%ED%9A%8C%EC%82%AC_%EC%95%94%EC%B9%98%EB%A3%8C%EC%A0%9C_FDA_%EC%9E%84%EC%83%811%EC%83%81_%EC%8B%9C%ED%97%98_%EC%8A%B9%EC%9D%B8&diff=22842&oldid=prev
Ihjung at 12:38, 16 October 2006
2006-10-16T12:38:00Z
<p></p>
<table class="diff diff-contentalign-left" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #222; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #222; text-align: center;">Revision as of 12:38, 16 October 2006</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l6" >Line 6:</td>
<td colspan="2" class="diff-lineno">Line 6:</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>         <tr></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>         <tr></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>             <td bordercolor="#66cc33" align="left" bgcolor="#cccccc"><strong>게재일</strong> : <font color="#ffffff">2006.10. 16</font></td></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>             <td bordercolor="#66cc33" align="left" bgcolor="#cccccc"><strong>게재일</strong> : <font color="#ffffff">2006.10. 16</font></td></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>             <td bordercolor="#66cc33" align="left" bgcolor="#cccccc"><strong>매체명</strong> :&nbsp;[http://<del class="diffchange diffchange-inline">www</del>.<del class="diffchange diffchange-inline">mkeconomy</del>.com <del class="diffchange diffchange-inline">매경이코노미</del>]</td></div></td><td class='diff-marker'>+</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>             <td bordercolor="#66cc33" align="left" bgcolor="#cccccc"><strong>매체명</strong> :&nbsp;[http://<ins class="diffchange diffchange-inline">economy</ins>.<ins class="diffchange diffchange-inline">hankooki</ins>.com <ins class="diffchange diffchange-inline">서울경제신문</ins>]<ins class="diffchange diffchange-inline">&nbsp;</ins></td></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>         </tr></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>         </tr></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>     </tbody></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>     </tbody></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div></table></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div></table></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"><p><br /></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"><font size="2">뉴젠비아이티는 16일 자회사인 바이오벤처기업 뉴젠팜과 미 헨리포드(Henry Ford) 병원이 미국 식품의약국(FDA)으로부터 유전자 항암치료제인 &lsquo;쎄라젠&rsquo;의 췌장암용 임상1상 시험 승인을 받았다고 밝혔다. </font></p></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"><p><font size="2">원용태 뉴젠비아이티 대표는 &ldquo;췌장암은 진단 후 일반적으로 6개월을 넘기지 못하고 사망하며 5년 생존율이 3%에 불과할 정도로 무서운 암&rdquo;이라며 &ldquo;췌장암용 쎄라젠 임상을 완료하면 아직까지 치료제가 전무한 췌장암 치료에 일대 혁명을 일으킬 것&rdquo;이라고 말했다. </font></p></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"><p><font size="2">그는 &ldquo;이미 지난 7월 미국 FDA 임상1상 시험을 완료한 전립선암용 쎄라젠은 임상1상의 고무적인 시험 결과에 따라 임상 2상을 생략하고 곧바로 임상3상 시험을 진행중&rdquo;이라고 덧붙였다. </font></p></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"><p><font size="2">세계보건기구(WHO) 통계에 따르면 암 환자수는 오는 2020년까지 전립선암 100만명, 췌장암 45만명에 달한다. 이에 따라 암치료제 시장규모가 전립선암 연간 30조원, 췌장암은 연간 14조원에 이를 것으로 전망된다. </font></p></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"><p><br /></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"><font size="2">한기석 기자 </font><a href="mailto:hanks@sed.co.kr"><font size="2">hanks@sed.co.kr</font></a><font size="2"> <br /></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"></font></p></ins></div></td></tr>
</table>
Ihjung
http://Opengenome.net/index.php?title=%EB%89%B4%EC%A0%A0%EB%B9%84%EC%95%84%EC%9D%B4%ED%8B%B0_%EC%9E%90%ED%9A%8C%EC%82%AC_%EC%95%94%EC%B9%98%EB%A3%8C%EC%A0%9C_FDA_%EC%9E%84%EC%83%811%EC%83%81_%EC%8B%9C%ED%97%98_%EC%8A%B9%EC%9D%B8&diff=22841&oldid=prev
Ihjung at 12:37, 16 October 2006
2006-10-16T12:37:05Z
<p></p>
<p><b>New page</b></p><div><table style="WIDTH: 578px; HEIGHT: 71px" cellpadding="5" width="578" border="0" class="subject"><br />
<tbody><br />
<tr><br />
<td class="title" bordercolor="#66cc33" bgcolor="#999999" colspan="2"><font color="#ffffff">뉴젠비아이티 자회사 암치료제 FDA 임상1상 시험 승인 </font></td><br />
</tr><br />
<tr><br />
<td bordercolor="#66cc33" align="left" bgcolor="#cccccc"><strong>게재일</strong> : <font color="#ffffff">2006.10. 16</font></td><br />
<td bordercolor="#66cc33" align="left" bgcolor="#cccccc"><strong>매체명</strong> :&nbsp;[http://www.mkeconomy.com 매경이코노미]</td><br />
</tr><br />
</tbody><br />
</table></div>
Ihjung